We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+9.12%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.39B
AUM Growth
-$132M
Cap. Flow
-$296M
Cap. Flow %
-5.49%
Top 10 Hldgs %
30.62%
Holding
156
New
15
Increased
31
Reduced
31
Closed
25

Top Buys

Rank Stock Value
1
THRD
Third Harmonic Bio
THRD
+$104M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$90.6M
3
TMO icon
Thermo Fisher Scientific
TMO
+$49.7M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$47.8M
5
BLU
BELLUS Health Inc.
BLU
+$33.8M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$168M
2
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$151M
3
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$108M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$81.3M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$65.3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.05%
2 Miscellaneous 1.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EVH icon
26
Evolent Health
EVH
$450M
$71.7M 1.33%
1,994,717
+216,717
+12% +$7.63M
PRLD icon
27
Prelude Therapeutics
PRLD
$354M
$66.4M 1.23%
10,039,691
– –
NTRA icon
28
Natera
NTRA
$50.4B
$66M 1.22%
1,505,153
-156,200
-9% -$7.44M
KROS icon
29
Keros Therapeutics
KROS
$219M
$63.2M 1.17%
1,679,417
– –
CRNX
30
DELISTED
Crinetics Pharmaceuticals
CRNX
$62.8M 1.17%
3,196,876
– –
MRSN
31
DELISTED
Mersana Therapeutics
MRSN
$60.9M 1.13%
360,457
– –
BIIB icon
32
Biogen
BIIB
$31.9B
$60M 1.11%
224,600
+113,000
+101% +$24M
SIBN icon
33
SI-BONE Inc
SIBN
$843M
$58.8M 1.09%
3,368,000
– –
VRNA
34
DELISTED
Verona Pharma
VRNA
$58.2M 1.08%
5,694,841
– –
ARQT icon
35
Arcutis Biotherapeutics
ARQT
$2.97B
$53.5M 0.99%
2,800,000
-1,981,646
-41% -$44.9M
GH icon
36
Guardant Health
GH
$23.8B
$53.4M 0.99%
992,400
-41,000
-4% -$2.1M
XTNT icon
37
Xtant Medical Holdings
XTNT
$45.2M
$52.6M 0.98%
73,114,592
+170,674
+0.2% +$93.5K
ALNY icon
38
Alnylam Pharmaceuticals
ALNY
$32.4B
$50.1M 0.93%
+250,500
New +$47.8M
CMPX icon
39
Compass Therapeutics
CMPX
$339M
$50.1M 0.93%
21,960,850
– –
BLU
40
DELISTED
BELLUS Health Inc.
BLU
$49M 0.91%
4,634,900
+3,180,100
+219% +$33.8M
KNTE
41
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$48.3M 0.9%
4,043,629
– –
SNDX icon
42
Syndax Pharmaceuticals
SNDX
$1.61B
$48.2M 0.9%
2,006,500
-316,800
-14% -$7.11M
SPRY icon
43
ARS Pharmaceuticals
SPRY
$431M
$46.2M 0.86%
8,740,887
– –
TERN
44
DELISTED
Terns Pharmaceuticals
TERN
$44.1M 0.82%
7,481,204
+3,690,000
+97% +$13.7M
ACRS icon
45
Aclaris Therapeutics
ACRS
$808M
$43.4M 0.81%
2,758,434
+432,934
+19% +$6.82M
PGNY icon
46
Progyny
PGNY
$2.14B
$42M 0.78%
1,134,053
+509,053
+81% +$19.1M
ABCL icon
47
AbCellera Biologics
ABCL
$3.74B
$41.3M 0.77%
4,180,768
– –
XENE icon
48
Xenon Pharmaceuticals
XENE
$5.51B
$41.1M 0.76%
1,137,300
-191,900
-14% -$6.9M
RPTX
49
DELISTED
Repare Therapeutics
RPTX
$40.3M 0.75%
3,322,488
– –
KDNY
50
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$39.9M 0.74%
2,029,300
+133,000
+7% +$2.67M
1
2
3 4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q3 2022 Portfolio in Review

As of Q3 2022, OrbiMed held 156 positions worth $5.39B, down 2.4% from $5.52B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

OrbiMed withdrew a net $296M in Q3 2022, closing 25 positions and reducing 31 holdings. Its most notable exit was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $168M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Miscellaneous.

Against the trend, OrbiMed opened a new position in Third Harmonic Bio worth $110M.

  • OrbiMed's largest Q3 2022 buy was Third Harmonic Bio: 5,779,071 shares worth $110M.
  • OrbiMed added most to Sarepta Therapeutics in Q3 2022, an estimated $90.6M increase.
  • OrbiMed's biggest Q3 2022 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $81.3M.
  • OrbiMed fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2022, selling an estimated $168M.
  • OrbiMed's ten largest holdings make up 31% of its $5.39B portfolio in Q3 2022.
  • OrbiMed opened 15 new positions and closed 25 in Q3 2022.
  • OrbiMed's portfolio value fell 2.4% quarter-over-quarter to $5.39B.

Based on OrbiMed's 13F filing for Q3 2022, filed 14 Nov 2022.